Evidence map›Paper›PMID 35223991›Full record

ReviewFrontiers in molecular biosciences2022

CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma.

Yuxia Zhou, Cheng Li, Zhenping Wang, Shuangfeng Tan, Yiqi Liu, Hu Zhang, Xuefeng Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yuxia ZhouThe First Affiliated Hospital, Department of Medical Oncology, Hengyang Medical School, University of South China, Hengyang, China.
Cheng LiThe First Affiliated Hospital, Department of Medical Oncology, Hengyang Medical School, University of South China, Hengyang, China.
Zhenping WangThe First Affiliated Hospital, Department of Medical Oncology, Hengyang Medical School, University of South China, Hengyang, China.
Shuangfeng TanThe First Affiliated Hospital, Department of Medical Oncology, Hengyang Medical School, University of South China, Hengyang, China.
Yiqi LiuThe Second Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.
Hu ZhangThe First Affiliated Hospital, Department of Urology, Hengyang Medical School, University of South China, Hengyang, China.
Xuefeng LiThe First Affiliated Hospital, Department of Medical Oncology, Hengyang Medical School, University of South China, Hengyang, China.
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circular RNAs (circRNAs) are a type of long non-coding RNA with covalently closed loops that are naturally resistant to exoribonuclease. With the rapid development of high-throughput sequencing technologies and bioinformatics, increasing data suggest that circRNAs are abnormally expressed in renal cell carcinoma (RCC) and act as important regulators of RCC carcinogenesis and progression. CircRNAs play important biological roles in modulating cell proliferation, migration, invasion, apoptosis, and gemcitabine chemoresistance in RCC. Most of the circRNAs studied in RCC have been reported to be significantly associated with many clinicopathologic characteristics and survival parameters of RCC. The stability and specificity of circRNAs enable them potential molecular markers for RCC diagnosis and prognosis. Moreover, circRNAs have emerged as targets for developing new therapies, because they can regulate various signaling pathways associated with RCC initiation and progression. In this review, we briefly summarize the biogenesis, degradation, and biological functions of circRNAs as well as the potential clinical applications of these molecules for RCC diagnosis, prognosis, and targeted therapy.

Indexed as

biomarkerceRNACircRNAsrenal cell carcinomatargeted therapy

Identifiers

PMID35223991
PMCPMC8874010
OpenAlexW4211146422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.